clinical trial · NCT07177339
eValuating the Efficacy and Safety of InitiatinG depemokImab earLy therApy iN Chronic Obstructive Pulmonary Disorder (COPD) With Type 2 Inflammation
GlaxoSmithKline·phase3·recruiting·n = 1,196
Pulmonary Disease, Chronic ObstructiveDepemokimabPlacebo
brief summary
Depemokimab is being developed as a treatment for individuals with moderate to severe Chronic Obstructive Pulmonary Disorder (COPD). The aim of this study is to assess the efficacy and safety of early initiation of depemokimab as an add-on medicine in participants with moderate to severe COPD with type 2 inflammation.
started
Oct 20, 2025
primary completion
Nov 2, 2029
completion
Dec 14, 2029
last updated
Nov 25, 2025
official title
A Multicenter, Randomized, Double-blind, Parallel Group, Placebo-controlled Study of the Efficacy and Safety of Early Depemokimab Initiation as add-on Treatment in COPD Patients With Type 2 Inflammation
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol